This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Mizuho initiated coverage on Ocugen Inc (NASDAQ: OCGN) with a Buy rating and a price target of $5, reflecting an upside of almost 115%.
Mizuho views Ocugen as a high-risk, high-reward opportunity.
While the lead asset, a COVID-19 vaccine (Covaxin), offers potential near-term cash flow to help offset operational costs, Mizuho believes OCU400, a Phase 1/2 gene therapy for eye disease, is a more significant value driver for the company.
According to the analyst, the current stock price primarily reflects the value of Covaxin.
Related: Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years.
"If approved, we believe COVAXIN could be attractive to individuals in the US seeking a broad antibody response against multiple antigens or waiting for a traditionally made COVID-19 vaccine due to their discomfort with mRNA vaccines," Mizuho writes.
The stock price incorporates little to no value for OCU400, setting up a favorable risk/reward going into the first human efficacy data readout for OCU400 in 1H23.
The analyst models a 20% probability of success sales of $455 million ($2.3 billion unadjusted) in 2030 for five key inherited retinal diseases (with cumulative sales of $3.3 billion ($16.3 billion unadjusted) for 2026-2035E).
Price Action: OCGN shares are up 3.85% at $2.43 during the premarket session on the last check Tuesday.
Latest Ratings for OCGN
HC Wainwright & Co.
HC Wainwright & Co.
View More Analyst Ratings for OCGN
View the Latest Analyst Ratings
See more from Benzinga
Medtronic Q1 Earnings Within Expectation, Sees Higher Currency Headwind On FY23 Sales
Owl Creek Urges Cano Health Board To Consider Potential Sale
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.